These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26344113)

  • 1. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination.
    Kobiyama K; Jounai N; Aoshi T; Tozuka M; Takeshita F; Coban C; Ishii KJ
    Vaccines (Basel); 2013 Jul; 1(3):278-92. PubMed ID: 26344113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel strategies to improve DNA vaccine immunogenicity.
    Coban C; Kobiyama K; Aoshi T; Takeshita F; Horii T; Akira S; Ishii KJ
    Curr Gene Ther; 2011 Dec; 11(6):479-84. PubMed ID: 22023477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA vaccines: a simple DNA sensing matter?
    Coban C; Kobiyama K; Jounai N; Tozuka M; Ishii KJ
    Hum Vaccin Immunother; 2013 Oct; 9(10):2216-21. PubMed ID: 23912600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine Adjuvants: from 1920 to 2015 and Beyond.
    Di Pasquale A; Preiss S; Tavares Da Silva F; Garçon N
    Vaccines (Basel); 2015 Apr; 3(2):320-43. PubMed ID: 26343190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
    Ishii KJ; Kawagoe T; Koyama S; Matsui K; Kumar H; Kawai T; Uematsu S; Takeuchi O; Takeshita F; Coban C; Akira S
    Nature; 2008 Feb; 451(7179):725-9. PubMed ID: 18256672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The science of adjuvants.
    Kwissa M; Kasturi SP; Pulendran B
    Expert Rev Vaccines; 2007 Oct; 6(5):673-84. PubMed ID: 17931149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
    Iurescia S; Fioretti D; Rinaldi M
    Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.
    Karlsson I; Borggren M; Nielsen J; Christensen D; Williams J; Fomsgaard A
    Hum Vaccin Immunother; 2017 Aug; 13(8):1823-1830. PubMed ID: 28613978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.
    Suschak JJ; Williams JA; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):2837-2848. PubMed ID: 28604157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.
    Savelkoul HF; Ferro VA; Strioga MM; Schijns VE
    Vaccines (Basel); 2015 Mar; 3(1):148-71. PubMed ID: 26344951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine Potentiation by Combination Adjuvants.
    Levast B; Awate S; Babiuk L; Mutwiri G; Gerdts V; van Drunen Littel-van den Hurk S
    Vaccines (Basel); 2014 Apr; 2(2):297-322. PubMed ID: 26344621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical adjuvants for plasmid DNA vaccines.
    Greenland JR; Letvin NL
    Vaccine; 2007 May; 25(19):3731-41. PubMed ID: 17350735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances of vaccine adjuvants for infectious diseases.
    Lee S; Nguyen MT
    Immune Netw; 2015 Apr; 15(2):51-7. PubMed ID: 25922593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationally-designed vaccine adjuvants: separating efficacy from toxicity.
    Hauguel TM; Hackett CJ
    Front Biosci; 2008 Jan; 13():2806-13. PubMed ID: 17981755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in adjuvants for vaccines against infectious diseases.
    O'Hagan DT; MacKichan ML; Singh M
    Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate immune control of nucleic acid-based vaccine immunogenicity.
    Koyama S; Coban C; Aoshi T; Horii T; Akira S; Ishii KJ
    Expert Rev Vaccines; 2009 Aug; 8(8):1099-107. PubMed ID: 19627190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.
    Grunwald T; Ulbert S
    Clin Exp Vaccine Res; 2015 Jan; 4(1):1-10. PubMed ID: 25648133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.